Certain confidential information contained in this document, marked by [***], has been omitted because it is not material and would likely cause competitive harm to Cullinan Oncology, Inc. if publicly disclosed. PERFORMANCE STOCK UNIT AWARD AGREEMENT...Performance Stock Unit Award Agreement • August 10th, 2022 • Cullinan Oncology, Inc. • Biological products, (no disgnostic substances)
Pursuant to the Cullinan Oncology, Inc. 2021 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Cullinan Oncology, Inc. (the “Company”) hereby grants an award (this “Award”) of the number of performance-based Restricted Stock Units (“Performance Stock Units”) listed above (the “Base Award”) to the Grantee named above. Each Performance Stock Unit shall relate to one share of Common Stock, par value $0.0001 per share (the “Stock”) of the Company.
SHARE PURCHASE AGREEMENT BY AND AMONG Taiho Pharmaceutical Co., Ltd CULLINAN PEARL CORP. AND Cullinan Oncology, Inc May 11, 2022Share Purchase Agreement • August 10th, 2022 • Cullinan Oncology, Inc. • Biological products, (no disgnostic substances) • New York
THIS SHARE PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of May 11, 2022, by and among Taiho Pharmaceutical Co., Ltd, a Japanese corporation (“Purchaser”), Cullinan Pearl Corp., a Delaware corporation (the “Company”), and Cullinan Oncology, Inc., a Delaware corporation (the “Seller”). All capitalized terms that are used but not defined herein shall have the respective meanings ascribed thereto in Annex A.
ContractCo-Development Agreement • August 10th, 2022 • Cullinan Oncology, Inc. • Biological products, (no disgnostic substances) • New York
Certain confidential information contained in this document, marked by [*****], has been omitted because it is not material and would likely cause competitive harm to Cullinan Oncology, Inc. if publicly disclosed.
